TRADE NEWS: Agilent Technologies Introduces Liquid Chromatography Solution with Advanced Protein-Sizing Capabilities
1260 Infinity Multi-Detector Bio-SEC Solution Provides Unmatched Analytical Capacity for Large-Molecule Biotherapeutic Development
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced the 1260 Infinity Multi-Detector Bio-SEC Solution, the latest innovation in its complete line of Infinity liquid chromatography systems. This new size-exclusion chromatography (SEC) system features advanced light-scattering detection capabilities, fully bio-inert instrumentation, high-resolution columns and intuitive software. These features take SEC—the gold standard in protein aggregate analysis—to a whole new level of speed, sensitivity and reproducibility.
“Our powerful new SEC LC solution provides biopharmaceutical researchers with previously unattainable robust measurement capabilities with unmatched reproducibility.”
“The development of large-molecule protein biotherapeutics is expected to yield blockbuster effects on human clinical outcomes, but in order to achieve that success, the biopharmaceutical industry requires equally vigorous research, measurement and analysis technology to fully ensure the safety and efficacy of those compounds,” said Helmut Schulenberg-Schell, director of business development for Agilent’s Liquid Phase Separation Division. “Our powerful new SEC LC solution provides biopharmaceutical researchers with previously unattainable robust measurement capabilities with unmatched reproducibility.”
SEC is used for protein sizing and studying aggregates and bio-conjugates. Even at the lowest concentrations, these “mis-folded” proteins that accumulate together in recombinant protein and monoclonal antibody biologics can be toxic and cause disease-producing effects. They must be identified and remediated at every phase of the drug development lifecycle—from early research, to clinical formulation, to large-scale manufacturing.
Agilent’s fully bio-inert 1260 Infinity Multi-Detector Bio-SEC Solution provides maximum sensitivity and accuracy through advanced detection capabilities and sophisticated yet intuitive software capabilities. Used throughout the drug development lifecycle, this technology can significantly simplify and speed up workflow, reducing the valuable time and expense associated with bringing biopharmaceuticals to market.
Learn more about the new 1260 Infinity Multi-Detector Bio-SEC Solution and Agilent’s complete Infinity series liquid chromatography portfolio at www.agilent.com/chem/infinity.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.